|
|
News Breaks | | | | February 14, 2013 | | 07:32 EDT |  | AVEO | Aveo Pharmaceuticals weakness unwarranted, says RBC Capital
RBC Capital believes that the weakness in Aveo's shares is unwarranted, as the firm doesn't think that details about the company's tivozanib treatment shed light on its approvability. RBC Capital thinks that tivozanib's risk-benefit profile is favorable, and it maintains an Outperform rating on the shares. | |
|
News For AVEO From The Last 14 Days Check below for free stories on AVEO the last two weeks. |
|
|
| There are no results for AVEO |
|
|
|
|
|
|
